Efficacy and safety of PCSK9 inhibitors in patients with chronic kidney disease
Abstract Background This study aimed to assess the efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in lowering lipid levels among chronic kidney disease (CKD) patients, including those with stages 4–5 CKD. Methods CKD patients with atherosclerotic cardiovascul...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-08-01
|
| Series: | BMC Nephrology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12882-025-04347-1 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|